Literature DB >> 24170201

Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer.

Pradeep S Tanwar1, Gayatry Mohapatra, Sarah Chiang, David A Engler, Lihua Zhang, Tomoko Kaneko-Tarui, Yasuyo Ohguchi, Michael J Birrer, Jose M Teixeira.   

Abstract

Epithelial ovarian cancer presents mostly with serous, endometrioid or mucinous histology but is treated as a single disease. The development of histotype-specific therapy has been challenging because of the relative lack of studies attributing disrupted pathways to a distinct histotype differentiation. mTOR activation is frequently associated with poor prognosis in serous ovarian cancer, which is the most common and most deadly histotype. However, the mechanisms dysregulating mTOR in the pathogenesis of ovarian cancer are unknown. We detected copy number loss and correlated lower expression levels of LKB1, TSC1, TSC2 and PTEN tumor suppressor genes for upstream regulators of mTOR activity in up to 80% in primary ovarian serous tumor databases, with LKB1 allelic loss-predominant. Reduced LKB1 protein was usually associated with increased mTOR activity in both serous ovarian cancer cell lines and primary tumors. Conditional deletion of Lkb1 in murine ovarian surface epithelial (OSE) cells caused papillary hyperplasia and shedding but not tumors. Simultaneous deletion of Lkb1 and Pten, however, led to development of high-grade ovarian serous histotype tumors with 100% penetrance that expressed WT1, ERα, PAX8, TP53 and cytokeratin 8, typical markers used in the differential diagnosis of serous ovarian cancer. Neither hysterectomy nor salpingectomy interfered with progression of ovarian tumorigenesis, suggesting that neither uterine nor Fallopian tube epithelial cells were contributing to tumorigenesis. These results implicate LKB1 loss in the OSE in the pathogenesis of serous ovarian cancer and provide a compelling rationale for investigating the therapeutic potential of targeting LKB1 signaling in patients with this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24170201      PMCID: PMC3941742          DOI: 10.1093/carcin/bgt357

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  50 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene.

Authors:  Ralf Lesche; Matthias Groszer; Jing Gao; Ying Wang; Albee Messing; Hong Sun; Xin Liu; Hong Wu
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

3.  Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity.

Authors:  Johanna I Partanen; Topi A Tervonen; Mikko Myllynen; Essi Lind; Misa Imai; Pekka Katajisto; Gerrit J P Dijkgraaf; Panu E Kovanen; Tomi P Mäkelä; Zena Werb; Juha Klefström
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

4.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

5.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Authors:  Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

6.  High-grade serous ovarian cancer arises from fallopian tube in a mouse model.

Authors:  Jaeyeon Kim; Donna M Coffey; Chad J Creighton; Zhifeng Yu; Shannon M Hawkins; Martin M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

7.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Authors:  Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

9.  Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder.

Authors:  Boris Y Shorning; David Griffiths; Alan R Clarke
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

10.  Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN.

Authors:  Pradeep S Tanwar; LiHua Zhang; Tomoko Kaneko-Tarui; Michael D Curley; Makoto M Taketo; Poonam Rani; Drucilla J Roberts; Jose M Teixeira
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

View more
  32 in total

1.  Expression and transcriptional profiling of the LKB1 tumor suppressor in cervical cancer cells.

Authors:  Xiaoli Zhang; Hanxiang Chen; Xiao Wang; Weiming Zhao; Jason J Chen
Journal:  Gynecol Oncol       Date:  2014-05-02       Impact factor: 5.482

2.  LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN.

Authors:  Juelan Wang; Wenqian Xu; Yangke He; Qi Xia; Siwei Liu
Journal:  Inflamm Res       Date:  2018-10-11       Impact factor: 4.575

3.  Hyperplasia and fibrosis in mice with conditional loss of the TSC2 tumor suppressor in Müllerian duct mesenchyme-derived myometria.

Authors:  Tomoko Kaneko-Tarui; Arno E Commandeur; Amanda L Patterson; Justin L DeKuiper; David Petillo; Aaron K Styer; Jose M Teixeira
Journal:  Mol Hum Reprod       Date:  2014-09-04       Impact factor: 4.025

4.  Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.

Authors:  Renaud Sabatier; Séverine Garnier; Arnaud Guille; Nadine Carbuccia; Jihane Pakradouni; José Adelaide; Magali Provansal; Maria Cappiello; Frédérique Rousseau; Max Chaffanet; Daniel Birnbaum; Emilie Mamessier; Anthony Gonçalves; François Bertucci
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

5.  LKB1 is physiologically required for sleep from Drosophila melanogaster to the Mus musculus.

Authors:  Ziyi Liu; Lifen Jiang; Chaoyi Li; Chengang Li; Jingqun Yang; Jianjun Yu; Renbo Mao; Yi Rao
Journal:  Genetics       Date:  2022-07-04       Impact factor: 4.402

Review 6.  Controlling the master-upstream regulation of the tumor suppressor LKB1.

Authors:  Lars Kullmann; Michael P Krahn
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

7.  Regulatory network involving miRNAs and genes in serous ovarian carcinoma.

Authors:  Haiyan Zhao; Hao Xu; Luchen Xue
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

8.  Specific deletion of LKB1/Stk11 in the Müllerian duct mesenchyme drives hyperplasia of the periurethral stroma and tumorigenesis in male mice.

Authors:  Jitu W George; Amanda L Patterson; Pradeep S Tanwar; André Kajdacsy-Balla; Gail S Prins; Jose M Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-13       Impact factor: 11.205

9.  LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways.

Authors:  Keqiang Zhang; Jinghan Wang; Jinhui Wang; Frank Luh; Xiyong Liu; Lu Yang; Yun-Ru Liu; Leila Su; Yu-Chen Sh Yang; Peiguo Chu; Yun Yen
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

10.  METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.

Authors:  Xuehan Bi; Xiao Lv; Dajiang Liu; Hongtao Guo; Guang Yao; Lijuan Wang; Xiaolei Liang; Yongxiu Yang
Journal:  Cancer Gene Ther       Date:  2020-09-16       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.